Douglas J. Manion - 17 Mar 2023 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role: Pres and CEO, Director
Signature: /s/ Mark Ballantyne, Attorney-in-Fact
Issuer symbol: ACRS
Transactions as of: 17 Mar 2023
Net transactions value: +$49,532
Form type: 4
Filing time: 17 Mar 2023, 17:03:45 UTC
Previous filing: 09 Mar 2023
Next filing: 03 Aug 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ACRS	Common Stock	Purchase	$49,532	+6,300	+97%	$7.86	12,800	17 Mar 2023	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $7.86 to $7.8641, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Content

The price reported is a weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $7.86 to $7.8641, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.